title: American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
abstract: Multiple myeloma (MM) had a major presence at this meeting with 855 abstracts related to MM, 24 oral presentations and 106 posters. This, coupled with the record attendance at this year’s meeting, made it a positive year for patients and clinicians alike as much of the presented data are likely to lead to major advances in the field of myeloma. Key areas of focus included: high-risk smoldering disease, minimal residual disease for monitoring response to therapy, novel therapies in clinical trials, including carfilzomib and daratumumab, and imaging modalities for MM.
authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors: Siobhan V
authors: SV
authors: Glavey
authors: Irene M
authors: IM
authors: Ghobrial
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006405:Hematology / Q000193:education / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D009842:Oligopeptides / Q000627:therapeutic use; D012495:San Francisco; D012955:Societies, Medical; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009842:Oligopeptides; C556306:daratumumab; C524865:carfilzomib